ASH 2014 | Recent investigational advances in the management of relapsed/refractory myeloma
Paul Richardson
Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.
Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.
Related videos
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
Characterization of the immune impact of DARA by mass cytometry in multiple myeloma
Gareth Morgan
The MAIA study and other myeloma highlights from ASH 2018
Gareth Morgan
Characterization of exceptional responders to ASCT in multiple myeloma
Vincent Rajkumar
